Grants for Special district governments - Food and Nutrition

This funding opportunity provides significant financial support to U.S. higher education institutions and research organizations with established HIV/AIDS research programs, enabling them to enhance their research infrastructure and foster interdisciplinary collaboration in the fight against HIV/AIDS.

This funding opportunity provides financial support to research institutions for developing and sharing essential resources to advance the study of Polycystic Kidney Disease, fostering collaboration and innovation in the field.

This funding opportunity provides financial support to public and nonprofit organizations to deliver comprehensive primary health care services in underserved communities across the United States.

This funding opportunity provides financial support to organizations implementing strategies to prevent diabetes and improve health equity for populations at risk, focusing on statewide, local, or multisectoral approaches.

The Silvio O. Conte Digestive Diseases Research Core Centers grant, provided by the NIDDK, supports collaborative research on digestive and liver diseases by offering shared resources to enhance productivity and foster new ideas, centered around a theme within the NIDDK's mission.

This funding opportunity supports research projects aimed at reducing stigma related to HIV/AIDS in low- and middle-income countries, with a focus on improving health outcomes for affected populations.

Addressing the Impact of Syndemics on the Health of People with HIV and Diseases and Conditions within the Missions of NIDDK and NHLBI (R01 Clinical Trial Optional)

This Notice of Funding Opportunity (NOFO) invites applications for a cooperative agreement to support, manage and facilitate Public-Private Partnerships and Collaborative activities as part of the Critical Path Initiative and to support regulatory science efforts. FDA and grantees will work together to develop innovative, collaborative projects in research, education, and outreach. These projects can help foster drug product innovation to 1) support efforts to accelerate drug product development; 2) support approaches to advanced manufacturing; 3) facilitate translation of basic science discoveries into therapeutics; and 4) facilitate approaches to enhance the safety, efficacy, quality, and performance of drug products. Projects are identified by FDA. Multiple awards may be funded under this NOFO and are directly dependent on drug development priorities and subject to the availability of funding.

This funding opportunity supports research projects that aim to improve the adoption and sustainability of effective health interventions, particularly in underserved communities, while also addressing the reduction of ineffective practices.

The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research.

This funding opportunity supports researchers in developing innovative tools that can speed up drug development and improve regulatory processes, ultimately enhancing public health by facilitating faster access to effective treatments.

This Notice of Funding Opportunity (NOFO) requests applications to explore human pancreatic tissues and the immune compartment for the discovery of specific signaling or processing pathways that may contribute to the asymptomatic phase of T1D, the discovery of early biomarkers of T1D pathogenesis, the development of diagnostic tools for the detection and staging of early T1D in at-risk or recently-diagnosed individuals, and/or the identification and biological validation of therapeutic targets for the development of preventative or early treatment strategies. Successful applicants will join the Consortium on Beta Cell Death and Survival (CBDS), whose mission is to better define and detect the mechanisms of beta cell stress and destruction central to the development of T1D in humans, with the long-term goal of protecting the residual beta cell mass in T1D patients as early as possible in the disease process, and of preventing the progression to autoimmunity. The CBDS is part of a collaborative research framework, the Human Islet Research Network (HIRN, https://hirnetwork.org/), whose overall mission is to support innovative and collaborative translational research to understand how human beta cells are lost in T1D, and to find innovative strategies to protect and replace functional beta cell mass in humans. This NOFO will only support studies with a primary focus on increasing our understanding of human disease biology (as opposed to rodent or other animal models). This NOFO will not accept applications proposing a clinical trial.

Notice of Funding Opportunity Description Background The Food and Drug Administration (FDA) protects the public health by ensuring that medical products intended to be marketed in the United States are safe and effective for their intended use. FDA stakeholders are exploring innovative ways to produce scientific evidence in support of regulatory submissions, including the development of new data sources, study designs, methodologies, and technologies. FDA encourages and facilitates the use of such innovative approaches while ensuring that the scientific evidence supporting marketing approvals meet our high evidentiary standards. The Prescription Drug User Fee Act VII (PDUFA VII) commitment letter represents the product of discussions between the FDA, regulated industry, and public stakeholders, as mandated by Congress. The performance and procedural goals and other commitments specified in the PDUFA VII commitment letter apply to aspects of the human drug review program that are important for facilitating timely access to safe, effective, and innovative new medicines for patients. The commitment letter includes goals relating to the use of digital health technologies (DHTs) to support drug development and review. A DHT is a system that uses computing platforms, connectivity, software, and/or sensors, for health care and related uses. DHTs for remote data acquisition in clinical investigations can include hardware and/or software to perform one or more functions. DHTs may rely on or work with other technologies that support their operation, such as general-purpose computing platforms (e.g., smartphones) and communication networks. Among other activities relating to the use of DHTs, FDA has established a Framework for the Use of DHTs in Drug and Biological Product Development to guide the use of DHT-derived data in regulatory decision-making for drugs (hereinafter Framework ). The Framework highlights FDA’s DHT efforts including workshops and demonstration projects; engagement with stakeholders; establishment of internal processes to support the evaluation of DHTs for use in drug development; promotion of shared learning and consistency regarding DHT-based policy, procedure, and analytic tool development; and publication of guidance documents. In addition, FDA’s webpage DHTs for Drug Development (available at: https://www.fda.gov/science-research/science-and-research-special-topics/digital-health-technologies-dhts-drug-development) provides an overview of the ongoing DHT efforts, including demonstration projects. A variety of project types are welcomed under this NOFO, applicable to drugs and biologics (not devices). FDA is particularly interested in projects that evaluate the use of DHTs in drug development. Project Objectives The overarching goal of this notice of funding opportunity (NOFO) is to explore the role of DHTs (e.g., actigraphy, photography, environmental sensors) in the evaluation of new drugs. These projects may involve engagement with researchers from academia, the biopharmaceutical industry, patient groups, and other stakeholders. The objectives of these projects are to advance DHTs for clinical drug development, expand the ability to capture early manifestations of chronic diseases, determine outcomes in populations with unmet medical needs and enhance convenience for trial participants by allowing for remote data acquisition in clinical investigations. The scope includes, but is not limited to, projects that focus on: Comparing digital measurements to traditional measurements in clinical trials to evaluate drugs Developing and evaluating novel endpoints using DHTs to address unmet needs for drug clinical trials (e.g., use of environmental sensors to capture apnea in pediatric patients) Comparing metrics to evaluate continuous measurements (e.g., maximum activity and stamina) Capturing early manifestations of chronic diseases (e.g., dementia) through the use of DHTs

The Rose Foundation for Communities and the Environment, in partnership with the Bay Foundation of Morro Bay, is offering a grant opportunity through the Central Coast Community-Based Water Quality Grants Program. This initiative focuses on supporting water quality-related projects within the Central Coast Regional Water Quality Control Board’s jurisdiction. The program's core mission aligns with the Rose Foundation's broader goals of fostering environmental health and community well-being, specifically by addressing critical water issues in California's Central Coast. The program primarily targets projects that advance environmental justice and provide water quality benefits to underrepresented communities. This focus aims to address historical inequities and ensure that all communities have access to clean and safe water. The expected outcomes include tangible improvements in water quality, enhanced environmental justice outcomes, and increased resiliency for communities facing water-related challenges. Measurable results will likely involve reductions in pollutant loading, progress toward water quality objectives, and the preservation and restoration of watershed functions. Key priorities and preferred topic areas for this grant include the human right to water, environmental justice capacity building, and understanding the water quality impacts of climate change. The program also emphasizes drought-related water supply resiliency, climate adaptation and mitigation, sustainable drinking water and wastewater treatment, and sustainable groundwater management strategies. Additionally, projects that benefit marine habitats in San Luis Obispo County, reduce pollutant loading to meet Central Coast Basin Plan objectives, restore impaired waterbodies, implement on-farm Best Management Practices to reduce salt and nitrate, and prevent or address Harmful Algal Blooms are highly encouraged. The grant offers two funding tracks: a Large Grant Track for requests up to $200,000 (with most awards between $100,000-$200,000) and a Small Grant Track for requests up to $50,000 (with most awards between $20,000-$50,000). Eligible applicants include 501(c)(3) nonprofit organizations, federally recognized and State Indian tribes, and public agencies with jurisdiction over water resources management. All projects must be conducted within the Central Coast Water Board's Region 3 jurisdiction, encompassing Southern Santa Clara, Santa Cruz, San Benito, Monterey, San Luis Obispo, Santa Barbara, and portions of Ventura, Kern, and San Mateo Counties. The foundation's strategic approach underscores a commitment to community-driven solutions and measurable environmental impact through collaborative partnerships.

This funding opportunity supports innovative research that investigates how aging affects individuals living with HIV, focusing on improving their health outcomes and addressing related challenges.

This funding opportunity supports innovative, interdisciplinary research projects that aim to fill critical knowledge gaps and advance scientific understanding in areas related to kidney, diabetes, and digestive diseases.

This funding opportunity supports students enrolled in dual-degree medical and research training programs, helping them develop into independent physician-scientists through mentored research and clinical training.

This funding opportunity supports clinical trials aimed at developing new therapies for rare neurodegenerative diseases, such as ALS, and is open to a wide range of eligible organizations, including universities and nonprofits.

This funding opportunity supports research initiatives focused on non-communicable diseases related to HIV at institutions in low- and middle-income countries, encouraging innovative projects and collaborations to improve health outcomes for people living with HIV.

This Notice of Funding Opportunity (NOFO) seeks to foster new multi-disciplinary teams to address how HIV Comorbidities and co-infections within the missions of NIDDK and NIAID interact with viral reservoirs, potentially confounding cure strategies aimed at either sustained viral suppression or elimination from the body. These teams will mechanistically interrogate the impact of inflammation, metabolic perturbations, or other pathophysiological processes associated with these comorbidities or co-infections on reservoir dynamics, and/or the interplay of these conditions and co-infections on HIV reservoir biology in ways that are likely to interact with potential cure strategies.